RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.

Revolution Medicines reports quarterly operating losses that widened from $175.7M in 2024Q3 to $373.1M in 2026Q3, driven by R&D expense rising from $151.8M to $417.1M, which suggests the equity story depends on pipeline success rather than current earnings.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue was effectively zero for most of the ten-quarter window before a single $197.6M print in 2026Q3, while operating margin deteriorated to -188.9% as R&D of $417.1M dominated the cost base, suggesting cost growth has far outpaced any visible revenue base.
Revolution Medicines plans to initiate pivotal combination studies in 2026 with zoldonrasib or elironrasib, with clinical data expected in 2025.
The stock has surged 97% year-to-date, indicating strong investor confidence in the company's potential.
Clinical data supporting the 2026 pivotal studies is anticipated in Q2 or Q3 2025, which could serve as a catalyst.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$1.90+19.1% vs -$2.35 | $198M+672.4% vs $26M |
Q3 2026 Aug 5, 2026 | -$3.06-50.0% vs -$2.04 | — vs $2M |
Q2 2026 May 6, 2026 | -$2.29-24.5% vs -$1.84 | — vs $2M |
Q1 2026 Feb 25, 2026 | -$1.86-17.7% vs -$1.58 | — vs $4M |
RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Aberdeen Group plc increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 303.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 576,371 shares of the company's stock after buying an additional 433,393 shares during the quarter.
Benchmark RVMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Revolution Medicines, Inc. (RVMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $162.69 | $34.59B | -18.69 | — | -946.82% | -91.93% | — | |
| $6.82 | $440.03M | -46.94 | -0.3% | -3.45% | -2% | — | |
| $1.44 | $82.51M | -1.88 | — | — | -43.99% | — | |
| $22.11 | $3.6B | -18.49 | 48.29% | — | -30.34% | — | |
| $121.52 | $10B | -34.81 | -16.72% | -341.87% | -22.39% | — | |
| $457.93 | $247.15B | 26.62 | 9.92% | 24.12% | 85.59% | 2.06% |
Revolution Medicines, Inc. (RVMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Revolution Medicines, Inc. (RVMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 22, 2026·SEC
May 6, 2026·SEC
Get notified when RVMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Revolution Medicines, Inc. (RVMD) stock FAQ — growth, dividends, profitability & financials explained
Revolution Medicines, Inc. (RVMD) reported $197.6M in revenue over the trailing twelve months.
No. Revolution Medicines, Inc. (RVMD) reported a net loss of $1.87B over the trailing twelve months.
Revolution Medicines, Inc. (RVMD) had a return on equity (ROE) of -91.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Revolution Medicines, Inc. (RVMD) had negative free cash flow of $1.44B over the trailing twelve months.